arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Context Therapeutics Inc.

CNTX

$0.48 ▼ -0.03 (-5.06%) at close

7 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Context Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $45.7M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -51.9% ↘

FCF / Share $-0.28 ↘

Trailing P/E —

Price / Book 0.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-36.12M

↓ -35.2% —

FCF / Share Free cash flow per share

$-0.28

↓ -11.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	17.4% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	69.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-61.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	74.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	—	—
Net Income Growth YoY (%)	-35.2% Weak ↑ Weak Improving Year-over-year change in net income	-11.5% Weak ↑ Weak Improving Year-over-year change in net income	-61.5% Weak Weak Year-over-year change in net income	-41.9% Weak Weak Year-over-year change in net income	N/M	—	—
FCF Growth YoY (%)	-11.3% Weak ↓ Weak Declining Year-over-year change in free cash flow	81.1% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-54.9% Weak ↓ Weak Declining Year-over-year change in free cash flow	72.6% Excellent Excellent Year-over-year change in free cash flow	-4.6% Weak Weak Year-over-year change in free cash flow	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
FCF / Net Income (x)	0.73x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.54x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	-0.16x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-51.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-24.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-166.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-35.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	12.0% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-58.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-30.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-156.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-40.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-20.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-550.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-59.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-498%)	-28.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-287%)	-201.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1446%)	-42.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-385%)	-21.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-244%)	-39.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-362%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	—	—	—	—	-163.85x Weak Weak Operating income divided by interest expense Optimal: > 5x	-3.89x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-66.00M	$-94.43M	$-14.45M	$-35.50M	$-49.64M	$-290.67K	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-0.38	$-0.46	$-1.50	$-0.93	$-3.69	$3.07	—
Free Cash Flow per Share (USD)	$-0.28	$-0.25	$-1.32	$-0.85	$-3.11	$-2.97	—
Book Value per Share (USD)	$0.66	$1.06	$0.74	$2.18	$3.02	$-51.00	—
Tangible Book Value per Share (USD)	$0.66	$1.06	$0.74	$2.18	$3.02	$-51.00	—
Basic Weighted Avg Shares (shares)	95.19M	58.42M	15.97M	15.97M	2.83M	348,368	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$60.33M	$95.15M	$11.86M	$34.65M	$48.22M	$-9.25M	—
Total Equity (USD)	$60.47M	$95.27M	$11.87M	$34.76M	$48.27M	$-16.92M	$-23.96M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$16.25K	$10.88K	$12.04K	$9.27K	$0.00	—	—
Net Income, GAAP (USD)	$-36.12M	$-26.73M	$-23.96M	$-14.84M	$-10.46M	$6.64M	—
Operating Cash Flow (USD)	$-26.39M	$-14.56M	$-21.05M	$-13.55M	$-8.80M	$-1.03M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Context Therapeutics Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CNTX with peers